MihaylovaBEmbersonJBlackwellL, et al.Cholesterol Treatment Trialists’ (CTT) Collaboration. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet2012; 380: 581–590.
2.
CannonCPBlazingMAGiuglianoRP, et al.Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med2015; 372: 2387–2397.
3.
SabatineMSGiuglianoRPKeechAC, et al.Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med2017; 376: 1713–1722.
4.
SchwartzGGStegPGSzarekM, et al.Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med2018; 379: 2097–2107.
5.
PiepoliMFHoesAWAgewallS, et al.Authors/Task Force Members. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: the Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts). Developed with the special contribution of the European Association for Cardiovascular Prevention and Rehabilitation (EACPR). Eur J Prev Cardiol2016; 23: NP1–NP96.
6.
ReinerŽDe BackerGFrasZ, et al.Lipid lowering drug therapy in patients with coronary heart disease from 24 European countries – findings from the EUROASPIRE IV survey. Atherosclerosis2016; 246: 243–250.
7.
FerrieresJDe FerrariGMHermansMP, et al.Predictors of LDL-cholesterol target value attainment differ in acute and chronic coronary heart disease patients: results from DYSIS II Europe. Eur J Prev Cardiol2018; 25: 1966–1976.
8.
MunkhaugenJSverreEOtterstadJE, et al.Medical and psychosocial factors and unfavourable low-density lipoprotein cholesterol control in coronary patients. Eur J Prev Cardiol2017; 24: 981–989.
9.
RamosRBallóEMarrugatJ, et al.Validity for use in research on vascular diseases of the SIDIAP (Information System for the Development of Research in Primary Care): the EMMA study. Rev Esp Cardiol (Engl Ed)2012; 65: 29–37.
10.
WürtzPWangQSoininenP, et al.Metabolomic profiling of statin use and genetic inhibition of HMG-CoA reductase. J Am Coll Cardiol2016; 67: 1200–1210.
11.
AlterDATuJVKohM, et al.Projected real-world effectiveness of using aggressive low-density lipoprotein cholesterol targets among elderly statin users following acute coronary syndromes in Canada. J Am Heart Assoc2018; 7(10): pii: e007535. DOI: 10.1161/JAHA.117.007535–pii: e007535. DOI: 10.1161/JAHA.117.007535.
12.
RavnskovUDiamondDMHamaR, et al.Lack of an association or an inverse association between low-density-lipoprotein cholesterol and mortality in the elderly: a systematic review. BMJ Open2016; 6: e010401–e010401.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
